Navigation Links
Jazz Pharmaceuticals Announces Presentation at the UBS Global Life Sciences Conference in New York on September 20
Date:9/16/2011

PALO ALTO, Calif., Sept. 16, 2011 /PRNewswire/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) announced today that the company will make a presentation at the UBS Global Life Sciences Conference in New York on Tuesday, September 20, 2011 at 9:30 a.m. Eastern Time. Company management will provide a business and financial update.  

A live webcast of the presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary to listen to the webcast.

An archived version of webcast will be available for at least one week on the Investors section of the company's website at www.jazzpharmaceuticals.com.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) is a specialty pharmaceutical company that identifies, develops and commercializes innovative treatments for important, underserved markets in neurology and psychiatry. For further information, see www.jazzpharmaceuticals.com.


'/>"/>
SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, Inc. ... clinical-stage biopharmaceutical company developing new treatments for cancer ... closing of its previously announced underwritten public offering ... a public offering price of $2.00 per share, ... offering expenses payable by Sorrento.  The net proceeds ...
(Date:4/19/2017)... Calif. , April 19, 2017  SARES•REGIS ... buildings it is developing at Conejo Spectrum Business ... , to Atara Biotherapeutics, Inc. , a ... severe and life-threatening diseases that have been underserved ... allogeneic T-cell therapies for cancer, autoimmune and infectious ...
(Date:4/18/2017)... -- Research and Markets has announced the addition of ... offering. ... market to grow at a CAGR of 6.35% during the period ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... April 26, 2017 , ... Datos Health , developer of ... Med-e-Mass , the largest Electronic Medical Records (EMR) provider in South Africa. ... incentives to a patient’s remote health progress, empowering the patient to take direct responsibility ...
(Date:4/26/2017)... ... ... Infertility may be a result of an underlying pelvic ... become pregnant upon treating their diagnosis. , To properly diagnose patients, ... can provide the necessary information to diagnose and treat your problem. , ...
(Date:4/26/2017)... ... April 26, 2017 , ... Want to learn ... ( CRISPRCas.pioneer.com ) that demonstrates how this advanced plant breeding technology is a ... food, with fewer resources. It highlights the business’ principles, research and collaboration efforts ...
(Date:4/26/2017)... ... April 26, 2017 , ... MYOLYN, a ... announce that it has received 510(k) clearance from the U.S. Food & Drug ... MyoCycle Pro. , Both devices are stationary cycling systems that use MYOLYN’s patent-pending ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... they have signed an agreement to be the preferred physical therapy provider for ... and returning them to Derby City CrossFit as quickly and effectively as possible, ...
Breaking Medicine News(10 mins):